Cannabis Producers Look to Differentiate-THC Therapeutics, Inc. (THCT)

May 21, 2019 -- InvestorsHub NewsWire -- via MicrocapSpeculators.com -- It’s been recently reported that some cannabis producers will have trouble moving their crop, which is why it will be key to differentiate their product from competitors. That’s why we’re highlighting THC Therapeutics, Inc. (THCT).

THC Therapeutics, Inc. (THCT) just made a major announcement; THCT announced Enzo Villani was appointed a member of the company’s Board of Directors. Mr. Villani is Co-Founder of Nasdaq Global Corporate Solutions Group.

Mr. Villani has raised over $500 million in funding from strategic investors, private equity, venture capital, family offices and the public markets during his over twenty-year career.

THCT’s dHydronator, can reduce moisture content of cannabis to 10% in only 10-14 hours. This is the same reason Aurora just signed a deal with EnWave. THCT received patent protection on 20 claims from the US patent office in March ’19 and will be using their patented designs to carve out their piece of the legal cannabis market expected to reach $146.4 billion by 2025.

Today we are highlighting: THC Therapeutics, Inc. (THCT), Aphria, Inc. (APHA), GW Pharmaceuticals plc (GWPH), The Green Organic Dutchman (TGODF), and Altria Group, Inc. (MO).

THC Therapeutics, Inc. (THCT) (Market Cap: $132.201M; Share Price: $9.60) has developed a sanitizing herb dryer, The dHydronator®. Their laboratory-proven product is specifically designed for drying and sanitizing freshly harvested cannabis and herbs. THCT’s product has been tested by two independent laboratories. The testing covered over 6 strains and 9 independent tests to confirm the findings. Over the 9 tests and 6 strains, there was a 4% average increase of THC-A*.

The US patent office has accepted ALL 20 claims for The dHydronator®. The company has received full patent protection for the dHydronator®. Start your research today on THCT.

________

Aphria Inc. (APHA) (Market Cap: $1.78B; Share Price: $7.03) shares fell after the Canadian cannabis company reported fiscal third-quarter results. It posted a C$108.2 million ($81.1 million) loss for its fiscal third quarter, or 43 cents a share, after a profit of C$12.9 million, or 8 cents a share, in the same period a year ago. Revenue climbed to C$73.6 million from C$10.3 million in the first full quarter of Canadian legal cannabis. But the company sold less cannabis than a year ago—kilograms sold fell to 2,636.5 from 3,408.9, while the average retail selling price for medical cannabis increased to C$8.03 per gram from C$7.51, primarily because of higher oil sales.

In April, it announced that the previously announced take-over bid (the "Offer") by Green Growth Brands Inc. ("GGB") has failed to meet the statutory minimum tender condition and has now expired and is terminated. As previously announced on April 15, 2019, the Company entered into a definitive agreement with GGB to accelerate the expiry date of the Offer to April 25, 2019, as well as to terminate certain arrangements with GA Opportunities Corp. ("GAOC") for consideration of $89.0 million payable on future dates as set out in the April 15th press release. The Offer is now expired and terminated and no longer open to any Aphria shareholder to tender their shares. Accordingly, GGB will not be taking up any securities that may have been tendered to the Offer. GGB will promptly return to the securityholder any Aphria shares tendered and not withdrawn during the period from the commencement of the Offer up to the expiry time of the Offer.

_________

GW Pharmaceuticals plc (GWPH) (Market Cap: $5.597B; Share Price: $182.21), the world leader in the development and commercialization of cannabinoid prescription medicines, recently announced the appointment of Darren Cline as its new U.S. Chief Commercial Officer. Mr. Cline will lead the Epidiolex^® U.S. commercial organization and is expected to start on April 22, 2019.

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia.

_________

The Green Organic Dutchman (TGODF) (Market Cap: $774.832M; Share Price: $2.91), recently participated in Virtual Investor Conferences.

The Green Organic Dutchman is an Ontario, Canada, based marijuana company that was IPO’d in spring 2018 and is currently valued at $957 million.

The Green Organic Dutchman expects that its production capacity will be 170,000 kg marijuana a year, based on several deals that have expanded the company’s asset base during 2018.

This includes the June 2018 acquisition of a facility (approximately 280,000 square foot) that The Green Organic Dutchman plans to use for producing marijuana-containing edible products and marijuana-infused beverages. It recently announced that effective March 25th, 2019 sales of certified-organic cannabis have started with national distribution to medical patients. The Growers' Circle is a select group of patients across Canada now receiving TGOD's first certified-organic flower.

_________

Altria Group, Inc. (MO) (Market Cap: $97.344B; Share Price: $52.03) announced that it has received a request for additional information (Second Request) from the U.S. Federal Trade Commission relating to its investment in JUUL Labs, Inc. that closed in December 2018.

Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, smokeless products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands. The company also produces and sells varietal and blended table wines, and sparkling wines.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a three-month term consulting agreement with THCT dated 2/14/18. The agreement calls for 50,000 restricted shares of THCT per month. This agreement has been amended to $20,000 per month, and 55,000 shares per month and extended for twelve months ending 3/18/2020. All payments were made directly by THC Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. THCT was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Full Legal Disclaimer Click Here.

Contact Information:

Company Name: ACR Communication LLC.

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024